Recruiting studies: T Cell Lymphoma Ptcl And Ctcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925 Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT05079282 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916 CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT06925464 CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 3 location(s) · Beijing GoBroad Hospital · NCT07022964 A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07055477 Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06810778

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.